NCT02963077View on ClinicalTrials.gov

A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Orphan Cholestatic Liver DiseasesPrimary Biliary CirrhosisProgressive Familial Intrahepatic CholestasisAlagille Syndrome
Interventions
DRUG

A4250

DRUG

CRC (A3384)

DRUG

Questran

DRUG

Placebo

Sponsors

Lead Sponsor

Albireo
All Listed Sponsors
lead

Albireo

INDUSTRY

NCT02963077 - A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 | Biotech Hunter | Biotech Hunter